Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema.
AIM: The study was a prospective randomised controlled double-masked trial performed in two centres to compare sub-threshold micropulse diode laser photocoagulation (MPDL) with conventional green laser photocoagulation (CGL) in the treatment of clinically significant diabetic macular oedema (CSMO)....
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2009
|
| _version_ | 1797084934250168320 |
|---|---|
| author | Figueira, J Khan, J Nunes, S Sivaprasad, S Rosa, A de Abreu, J Cunha-Vaz, J Chong, N |
| author_facet | Figueira, J Khan, J Nunes, S Sivaprasad, S Rosa, A de Abreu, J Cunha-Vaz, J Chong, N |
| author_sort | Figueira, J |
| collection | OXFORD |
| description | AIM: The study was a prospective randomised controlled double-masked trial performed in two centres to compare sub-threshold micropulse diode laser photocoagulation (MPDL) with conventional green laser photocoagulation (CGL) in the treatment of clinically significant diabetic macular oedema (CSMO). METHODS: Fifty-three patients (84 eyes) with diabetic CSMO were randomly assigned to MPDL (n = 44) or CGL (n = 40) according to the modified Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Treatments were performed after baseline and re-treatments were allowed at or after the 4 month visit if necessary. Parameters noted included the best corrected visual acuity (BCVA), colour fundus photographs, central retinal thickness using optical coherence tomography (OCT), vision contrast sensitivity with Pelli-Robson charts and presence of visible laser scars at baseline and at 4 and 12 months. The primary outcome was BCVA at 12 months. RESULTS: All patients completed 12 months of follow-up after treatment at baseline. There were no statistically significant differences in BCVA, contrast sensitivity and retinal thickness between the two laser modalities at 0, 4 and 12 months. We found that laser scarring was much more apparent with CGL than with the sub-threshold approach (MPDL). Laser scars were identified at the 12 month visits in 13.9% of the MPDL-treated eyes compared with 59.0% of the CGL-treated eyes (p<0.001). CONCLUSION: Sub-threshold micropulse diode laser photocoagulation is equally as effective as CGL treatment for CSMO. TRIAL REGISTRATION NUMBER: ISTRN 90646644. |
| first_indexed | 2024-03-07T02:02:05Z |
| format | Journal article |
| id | oxford-uuid:9db76216-f3e5-45e9-866d-a11ac421b6d4 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:02:05Z |
| publishDate | 2009 |
| record_format | dspace |
| spelling | oxford-uuid:9db76216-f3e5-45e9-866d-a11ac421b6d42022-03-27T00:45:03ZProspective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:9db76216-f3e5-45e9-866d-a11ac421b6d4EnglishSymplectic Elements at Oxford2009Figueira, JKhan, JNunes, SSivaprasad, SRosa, Ade Abreu, JCunha-Vaz, JChong, N AIM: The study was a prospective randomised controlled double-masked trial performed in two centres to compare sub-threshold micropulse diode laser photocoagulation (MPDL) with conventional green laser photocoagulation (CGL) in the treatment of clinically significant diabetic macular oedema (CSMO). METHODS: Fifty-three patients (84 eyes) with diabetic CSMO were randomly assigned to MPDL (n = 44) or CGL (n = 40) according to the modified Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Treatments were performed after baseline and re-treatments were allowed at or after the 4 month visit if necessary. Parameters noted included the best corrected visual acuity (BCVA), colour fundus photographs, central retinal thickness using optical coherence tomography (OCT), vision contrast sensitivity with Pelli-Robson charts and presence of visible laser scars at baseline and at 4 and 12 months. The primary outcome was BCVA at 12 months. RESULTS: All patients completed 12 months of follow-up after treatment at baseline. There were no statistically significant differences in BCVA, contrast sensitivity and retinal thickness between the two laser modalities at 0, 4 and 12 months. We found that laser scarring was much more apparent with CGL than with the sub-threshold approach (MPDL). Laser scars were identified at the 12 month visits in 13.9% of the MPDL-treated eyes compared with 59.0% of the CGL-treated eyes (p<0.001). CONCLUSION: Sub-threshold micropulse diode laser photocoagulation is equally as effective as CGL treatment for CSMO. TRIAL REGISTRATION NUMBER: ISTRN 90646644. |
| spellingShingle | Figueira, J Khan, J Nunes, S Sivaprasad, S Rosa, A de Abreu, J Cunha-Vaz, J Chong, N Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. |
| title | Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. |
| title_full | Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. |
| title_fullStr | Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. |
| title_full_unstemmed | Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. |
| title_short | Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. |
| title_sort | prospective randomised controlled trial comparing sub threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema |
| work_keys_str_mv | AT figueiraj prospectiverandomisedcontrolledtrialcomparingsubthresholdmicropulsediodelaserphotocoagulationandconventionalgreenlaserforclinicallysignificantdiabeticmacularoedema AT khanj prospectiverandomisedcontrolledtrialcomparingsubthresholdmicropulsediodelaserphotocoagulationandconventionalgreenlaserforclinicallysignificantdiabeticmacularoedema AT nuness prospectiverandomisedcontrolledtrialcomparingsubthresholdmicropulsediodelaserphotocoagulationandconventionalgreenlaserforclinicallysignificantdiabeticmacularoedema AT sivaprasads prospectiverandomisedcontrolledtrialcomparingsubthresholdmicropulsediodelaserphotocoagulationandconventionalgreenlaserforclinicallysignificantdiabeticmacularoedema AT rosaa prospectiverandomisedcontrolledtrialcomparingsubthresholdmicropulsediodelaserphotocoagulationandconventionalgreenlaserforclinicallysignificantdiabeticmacularoedema AT deabreuj prospectiverandomisedcontrolledtrialcomparingsubthresholdmicropulsediodelaserphotocoagulationandconventionalgreenlaserforclinicallysignificantdiabeticmacularoedema AT cunhavazj prospectiverandomisedcontrolledtrialcomparingsubthresholdmicropulsediodelaserphotocoagulationandconventionalgreenlaserforclinicallysignificantdiabeticmacularoedema AT chongn prospectiverandomisedcontrolledtrialcomparingsubthresholdmicropulsediodelaserphotocoagulationandconventionalgreenlaserforclinicallysignificantdiabeticmacularoedema |